Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Common Equity (2020 - 2025)

Biofrontera (BFRI) has 6 years of Common Equity data on record, last reported at -$2.6 million in Q3 2025.

  • For Q3 2025, Common Equity fell 146.67% year-over-year to -$2.6 million; the TTM value through Sep 2025 reached -$2.6 million, down 146.67%, while the annual FY2024 figure was $4.4 million, 7.51% down from the prior year.
  • Common Equity reached -$2.6 million in Q3 2025 per BFRI's latest filing, up from -$4.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $23.9 million in Q4 2022 and bottomed at -$17.4 million in Q3 2021.
  • Average Common Equity over 5 years is $6.0 million, with a median of $4.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 1359.72% in 2022, then plummeted 146.67% in 2025.
  • A 5-year view of Common Equity shows it stood at $11.3 million in 2021, then soared by 110.6% to $23.9 million in 2022, then plummeted by 79.93% to $4.8 million in 2023, then decreased by 7.51% to $4.4 million in 2024, then plummeted by 158.22% to -$2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$2.6 million in Q3 2025, -$4.7 million in Q2 2025, and $500000.0 in Q1 2025.